Efgartigimod showed sustained improvement in patients with generalized myasthenia gravis (gMG) and AChR autoantibodies, affirming its safety and efficacy in the ADAPT trial and extension. The therapy ...

FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune ...

In the quest to match its predecessor Soliris, Alexion's Ultomiris just notched a win in the autoimmune disorder myasthenia gravis. Alexion is trumpeting data showing Ultomiris met its primary ...

Please provide your email address to receive an email when new articles are posted on . Two observational studies compared videos of those with myasthenia gravis with healthy controls. A deep learning ...

A new study led by researchers at the UNC School of Medicine and Cartesian Therapeutics, found that immunotherapy can help people with generalized myasthenia gravis, a disease where the body ...

Myasthenia gravis develops when the body produces autoantibodies that interfere with the way nerves and muscles communicate. The disease can lead to severe attacks of weakness that cause swallowing ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Nicholas Silvestri ...

PHOENIX — Early responders to zilucoplan, the newly approved medication for myasthenia gravis (MG), have sustained benefit for up to 60 weeks, new analyses show. "The information [in the studies] is ...

Please provide your email address to receive an email when new articles are posted on . AstraZeneca has announced FDA approval of Ultomiris, a long-acting C5 complement inhibitor for the treatment of ...

The most notable strategic choice is prioritising myasthenia gravis (MG) and Sjögren's disease as lead indications while deprioritising lupus.

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open-label extension ...